: Drug Discovery Summit

Drug Discovery Summit

26 - 27 October 2021 | London, UK
+ Digital Day: 28 October 2021 | Online
22nd Annual
Drug Discovery Summit
26 - 27 October 2021 | London, UK
+ Digital Day: 28 October 2021 | Online

An invaluable resource for those looking to improve efficiency, increase pipelines and keep up to date with the latest advances. Featuring key insights into protein degradation, AI/ML in drug discovery, and much more

The Drug Discovery Summit features...

Over 400 attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions

A look at the future of drug discovery in new modalities such as protein degradation, RNA based therapeutics and case studies on the identification and Validation of Novel Targets

The latest updates on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling, and novel RNA drug targets

Insights into drug discovery strategies & next generation therapeutics, empowering drug discovery with chemical biology, target validation, drug profiling and protein degradation technologies

An evaluation of the Development of Clinical Biomarker translation and patient engagement

Supported digitally on our fully featured online event platform, with selected presentations available to watch on-demand and extensive networking features

Agenda at a Glance

Day One

Morning Sessions:

Stream 1: Identification and Validating Novel Targets – Case Study Presentations
Stream 2: Phenotypic Based Discovery & Screening Approaches
Stream 3: New Modalities And Challenging Targets: Targeted Protein Degradation and PROTAC

Afternoon Interactive Sessions:

Roundtable Discussions:
– Identification and Validating Novel Targets
– New Modalities And Challenging Targets: Targeted Protein Degradation & PROTAC

Workshops:
– Molecular Glue for New Drug Development Workshop
– E3 Ubiquitin Ligases and Targeted Protein Degradation
– Overview Of Available Methods To Characterize The Compound – Target Interaction On A Molecular Level Via SPR, MST, ITC and TSA

Day Two

Morning Sessions:

Stream 1: New Modalities And Challenging Targets: RNA based Therapeutics
Stream 2: Animal and Disease Modelling, Organoid based Discovery, 3D Media

Afternoon Interactive Sessions:

Roundtable Discussions:
– Target Discovery and Animal Modelling
– Translational Biomarkers and Patient Engagement

Workshop: Development And Identification Of Biomarkers, New Targets And Combination Therapies For Cancer

Key Speakers

The 2021 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

Jake Bush

Jake Bush

Director Chemical Biology
GSK
Eric Martin

Eric Martin

Director, Computational Chemistry
Novartis
Phil Cox

Phil Cox

Research Fellow, Head of Augmented Molecular Design, Drug Discovery Science and Technology
AbbVie
Ian Storer

Ian Storer

Vice President of Chemistry and Hit Discovery
AstraZeneca
Malcolm Weir

Malcolm Weir

Chief Executive Officer
Sosei Heptares
Thorsten Thormann

Thorsten Thormann

Vice President, Research
Leo Pharma
Janet Brownlees

Janet Brownlees

Director, Neuroscience Biology, Discovery Research MRL UK
MSD
Sarah Stuart

Sarah Stuart

HTC Team Leader, Biopharm Discovery
GSK
Bryn Williams-Jones

Bryn Williams-Jones

Vice President Drug Discovery
BenevolentAI
Victor Neduva

Victor Neduva

Director of Computational Biology, Discovery Research
MSD

Live Webinar

Application of In-Vitro and In-Vivo ADME/PK/Expl Tox assays to Support Lead and Candidate Selections

Wednesday, 18th November, 2020
10:00am GMT (UTC+0)

hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner